diabetes) and the titration schedules used to reach a maintenance dose
3.5 Strategic implications Taken together, the developments described abovenamely, the maturation of long-acting peptide design, the conceptual shift toward rational polypharmacology, the availability of improved mechanistic validation tools, and the evolution of clinical and regulatory expectationssuggest that the present moment represents an inflection point for underexplored peptidereceptor systems
GLP-1s appear to improve insulin signaling across the hypothalamic-pituitary-gonadal axis, which could explain these benefits
[9] STEP-1 : In patients with obesity without diabetes, semaglutide resulted in ~15% mean weight loss over 68 weeks
Liraglutide acts faster but requires daily dosing, while tirzepatide targets an additional hormone pathway that may make it more potent for weight loss
By day 3 of the first injection, appetite is noticeably reduced